Abstract Library

#2805 Small Bowel Neuroendocrine Tumor Metastases: Comparison of Contrast-Enhanced Computed Tomography and 68Ga-DOTATATE PET/CT

Introduction: Most gastrointestinal neuroendocrine tumors (GI-NETs) involve the small intestine (38%) and about 50% of patients present with regional or distant metastases at time of diagnosis [2]. 68Ga-DOTATATE PET/CT provides improved sensitivity and specificity compared to traditional nuclear medicine techniques [4]. However, there is relatively less data comparing performance of 68Ga-DOTATATE PET/CT with contrast-enhanced CT (CECT).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Monahan H, Packard A, Broski S, Goenka A, Kendi T,

Keywords: dotate, computed tomography, neuroendocrine tumor, small bowel, liver, lymph node, 68-gallium,

#315 The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors

Introduction: Accurate assessment of the primary tumor site and the extent of the metastatic burden are crucial and can be challenging, however, it is essential to the choice of optimal patient-tailored management.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Sotiropoulos G, Li J, Al-Nahhas A, Spalding D, Tedeschi M,

Keywords: neuroendocrine tumors, 68Ga-DOTATOC (or 68Ga-DOTATE) PET/CT, impact of surgical management,

#287 Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Carroll R, Tan T, Todd J, Al-Nahhas A, Bomanji J,

Keywords: 177Lutetium-DOTATATE therapy, neuroendocrine tumor, paraganglioma, SDHB,